Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Nafamostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 9/20 | 0.64 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.58 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.58 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.58 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.58 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.58 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.58 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.64 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.64 |
| ▸ | KLK1 | P06870 | 3/20 | 0.64 |
| ▸ | F10 | P00742 | 3/20 | 0.64 |
| ▸ | C1R | P00736 | 2/20 | 0.64 |
| ▸ | PLG | P00747 | 10/20 | 0.58 |
| ▸ | F12 | P00748 | 6/20 | 0.58 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL29832433 | 1.00 | FTO (0.70) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL1568755 | 1.00 | FTO (0.70) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL874941 | 0.95 | FTO (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL135503 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL29429445 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL16069975 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL29429443 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL3302794 | 0.93 | PRSS1 (0.63) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL7345508 | 0.91 | PRSS1 (0.62) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL7338487 | 0.90 | FTO (0.58) | FTOPRSS1F2KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120771360-B | Composite anticoagulation coating and preparation method and application thereof | Nanjing Hanke Mingde Medical Technology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-118439976-B | Nafamostat mesylate crystal form and preparation method thereof | 南京海纳医药科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-118576762-B | Double-layer core-shell structure artificial fiber dura mater for spinal cord injury and preparation method thereof | 山东大学齐鲁医院 | 2026-05-12 | — | — | CN | claimed |
| WO-2026089565-A1 | USE OF CATHEPSIN L INHIBITOR IN COMBINATION ADMINISTRATION | 연세대학교 산학협력단 | 2026-04-30 | — | — | WO | claimed |
| US-20250375413-A1 | METHOD OF INHIBITING LIPASE ACTIVITY IN AGING | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | claimed |
| US-20250345458-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-06-12 | — | — | US | claimed |
| US-20250152748-A1 | HYDRODYNAMIC GENE DELIVERY | UNIV JOHNS HOPKINS (US) | 2025-05-15 | — | — | US | claimed |
| US-20250099412-A1 | METHOD OF INHIBITING DEGRADING PROTEASE ACTIVITY IN AGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-03-27 | — | — | US | claimed |
| EP-4525916-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | Bexson Biomedical, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-20050228001-A1 | Methods and compositions for treating platelet-related disorders | COMERICA BANK | 2005-10-13 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| CN-1504580-A | Combination comprising thrombin agent and examining agent | 希森美康株式会社 | 2004-06-16 | — | — | CN | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0801953-B1 | Medical device for the extracorporal blood or plasma treatment and methods for the manufacture of such device | HOSPAL IND (FR) | 2002-07-03 | — | — | EP | claimed |
| US-6248238-B1 | SEMIPERMEABLE MEMBRANE CONSISTING OF A NEGATIVELY SURFACE-CHARGED ELECTRONEGATIVE POLYMER HAVING ADSORBED THEREON BEFORE STERILIZATION A CATIONIC PROTEASE INHIBITOR TO PREVENT KALLIKREIN-KININ ACTIVATION DURING DIALYSIS | HOSPAL INDUSTRIE (FR) | 2001-06-19 | — | — | US | claimed |
| US-5709993-A | Process for anticoagulation during extracorporeal blood circulation sequentially using citrate or nafamostat and heparin | BUTUROVIC-PONIKVAR JADRANKA (SI) | 1998-01-20 | — | — | US | claimed |
| WO-1996002288-A1 | PROCESS FOR PREVENTING ACTIVATION OF ENZYME SYSTEMS IN HAEMODIALYSIS AND IN SIMILAR PROCEDURES WITH EXTRACORPOREAL BLOOD CIRCULATION | BUTUROVIC PONIKVAR JADRANKA (SI) | 1996-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | TPMT, ADH1C, ADH1A | F2 1213/4885CHRM1 2852/4885DRD2 3619/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | F2 314/4885CHRM1 2836/4885DRD2 4607/4885 |
| US-20250345458-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | MC2R, SLC26A3, SLC5A1 | F2 1323/4885CHRM1 4393/4885DRD2 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.